Chemotherapy Induced Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 122 Published: April 04, 2022 Report Code: GMDGDHC22076IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech.org

Chemotherapy induced neutropenia pipeline market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Key Targets in the Chemotherapy Induced Neutropenia Pipeline Market

The key targets in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor, Caspase 3, Caspase 8, Caspase 9, Rho Guanine Nucleotide Exchange Factor 2, E Selectin, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha, Interleukin 1 Receptor, Signal Transducer And Activator Of Transcription, Signal Transducer and Activator Of Transcription 5. Granulocyte Colony Stimulating Factor Receptor has the highest number of pipeline products.

Chemotherapy Induced Neutropenia Pipeline Market, by Target

Chemotherapy Induced Neutropenia Pipeline Market, by Target

For more target insights, download a free report sample

Key MoA in the Chemotherapy Induced Neutropenia Pipeline Market

The key MoA in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor Agonist, Caspase 3 Activator, Caspase 8 Activator, Caspase 9 Activator, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha Agonist, and Rho Guanine Nucleotide Exchange Factor 2 Activator. Granulocyte Colony Stimulating Factor Receptor Agonist have the highest number of pipeline products.

Chemotherapy Induced Neutropenia Pipeline Market, by MoA

Chemotherapy Induced Neutropenia Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Chemotherapy Induced Neutropenia Pipeline Market

The key RoA in the chemotherapy induced neutropenia pipeline market are subcutaneous, intravenous, oral, and intramuscular. Subcutaneous has the highest number of pipeline products.

Chemotherapy Induced Neutropenia Pipeline Market, by RoA

Chemotherapy Induced Neutropenia Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Chemotherapy Induced Neutropenia Pipeline Market

The key molecule type in the chemotherapy induced neutropenia pipeline market are recombinant protein, fusion protein, small molecule, and cell therapy. Recombinant protein has the highest number of pipeline products.

Chemotherapy Induced Neutropenia Pipeline Market, by Molecule Type

Chemotherapy Induced Neutropenia Pipeline Market, by Molecule Type

For more insights, download a free report sample

Key Companies in the Chemotherapy Induced Neutropenia Pipeline Market

The key companies in the chemotherapy induced neutropenia pipeline market are Curateq Biologics Pvt Ltd, Hanmi Pharmaceuticals Co Ltd, USV Pvt Ltd, BeyondSpring Inc, Biocon Ltd 1, Bolder Biotechnology Inc, Evive Biotech, and Lupin Ltd. Curateq Biologics Pvt Ltd has the highest number of pipeline products.

Chemotherapy Induced Neutropenia Pipeline Market, by Companies

Chemotherapy Induced Neutropenia Pipeline Market, by Companies

To know about more companies, download a free report sample

Market report overview

Key targets Granulocyte Colony Stimulating Factor Receptor, Caspase 3, Caspase 8, Caspase 9, Rho Guanine Nucleotide Exchange Factor 2, E Selectin, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha, Interleukin 1 Receptor, Signal Transducer And Activator Of Transcription, Signal Transducer and Activator Of Transcription 5
Key MoA Granulocyte Colony Stimulating Factor Receptor Agonist, Caspase 3 Activator, Caspase 8 Activator, Caspase 9 Activator, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha Agonist, and Rho Guanine Nucleotide Exchange Factor 2 Activator
Key RoA Subcutaneous, Intravenous, Oral, and Intramuscular
Key molecule types Recombinant Protein, Fusion Protein, Small Molecule, and Cell Therapy
Key companies Curateq Biologics Pvt Ltd, Hanmi Pharmaceuticals Co Ltd, USV Pvt Ltd, BeyondSpring Inc, Biocon Ltd 1, Bolder Biotechnology Inc, Evive Biotech, and Lupin Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Apotex Inc

BeyondSpring Inc

Biocon Ltd

Biosimilar Solutions LLC

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

CSPC Pharmaceutical Group Ltd

Curateq Biologics Pvt Ltd

Dr. Reddy’s Laboratories Ltd

Enzychem Lifesciences Corp

Evive Biotech

FortuneRock (China) Ltd

General Regeneratives Shanghai Ltd

GlycoMimetics Inc

Hangzhou Jiuyuan Gene Engineering Co Ltd

Hanmi Pharmaceuticals Co Ltd

Ilkogen Ilac San Ve Tic AS

Jiangsu Aosaikang Pharmaceutical Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Karyo Biologics LLC

Kidswell Bio Corp

Ligand Pharmaceuticals Inc

Lupin Ltd

Mabwell Shanghai Bioscience Co Ltd

Mycenax Biotech Inc

Pangen Biotech Inc

Profarma

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Siam Bioscience Co Ltd

Tanvex BioPharma Inc

UBI Pharma Inc

USV Pvt Ltd

Valenta Pharm

Xiamen Amoytop Biotech Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Neutropenia – Overview

Chemotherapy Induced Neutropenia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Neutropenia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development

Apotex Inc

BeyondSpring Inc

Biocon Ltd

Biosimilar Solutions LLC

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

CSPC Pharmaceutical Group Ltd

Curateq Biologics Pvt Ltd

Dr. Reddy’s Laboratories Ltd

Enzychem Lifesciences Corp

Evive Biotech

FortuneRock (China) Ltd

General Regeneratives Shanghai Ltd

GlycoMimetics Inc

Hangzhou Jiuyuan Gene Engineering Co Ltd

Hanmi Pharmaceuticals Co Ltd

Ilkogen Ilac San Ve Tic AS

Jiangsu Aosaikang Pharmaceutical Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Karyo Biologics LLC

Kidswell Bio Corp

Ligand Pharmaceuticals Inc

Lupin Ltd

Mabwell Shanghai Bioscience Co Ltd

Mycenax Biotech Inc

Pangen Biotech Inc

Profarma

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Siam Bioscience Co Ltd

Tanvex BioPharma Inc

UBI Pharma Inc

USV Pvt Ltd

Valenta Pharm

Xiamen Amoytop Biotech Co Ltd

Chemotherapy Induced Neutropenia – Drug Profiles

BBT-007 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BBT-015 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Therapy for Chemotherapy Induced Neutropenia – Drug Profile

Product Description

Mechanism Of Action

efbemalenograstim alfa LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

eflapegrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgrastim – Drug Profile

Product Description

Mechanism Of Action

filgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgrastim – Drug Profile

Product Description

Mechanism Of Action

filgrastim – Drug Profile

Product Description

Mechanism Of Action

filgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgrastim – Drug Profile

Product Description

Mechanism Of Action

filgrastim biosimilar – Drug Profile

Product Description

Mechanism Of Action

GR-007 – Drug Profile

Product Description

Mechanism Of Action

GW-003 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GXG-3 – Drug Profile

Product Description

Mechanism Of Action

History of Events

imidazolyl ethanamide pentandioic acid – Drug Profile

Product Description

Mechanism Of Action

History of Events

lenograstim – Drug Profile

Product Description

Mechanism Of Action

LG-7455 – Drug Profile

Product Description

Mechanism Of Action

mosedipimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

pegfilgrastim – Drug Profile

Product Description

Mechanism Of Action

pegfilgrastim biosimilar – Drug Profile

Product Description

Mechanism Of Action

plinabulin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Agonize GCSFR for Chemotherapy Induced Neutropenia – Drug Profile

Product Description

Mechanism Of Action

romyelocel-L – Drug Profile

Product Description

Mechanism Of Action

History of Events

SFR-9314 – Drug Profile

Product Description

Mechanism Of Action

History of Events

UB-853 – Drug Profile

Product Description

Mechanism Of Action

uproleselan sodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

YPEG-Filgrastim – Drug Profile

Product Description

Mechanism Of Action

History of Events

Chemotherapy Induced Neutropenia – Dormant Projects

Chemotherapy Induced Neutropenia – Discontinued Products

Chemotherapy Induced Neutropenia – Product Development Milestones

Featured News & Press Releases

Feb 24, 2022: Yifan Pharma’s announcement on the progress of the F-627 Project

Dec 15, 2021: BeyondSpring Pharmaceuticals announces new clinical data confirming plinabulin’s fast onset mechanism of action in the prevention of chemotherapy-induced neutropenia at the 63rd ASH Annual Meeting and Exposition

Dec 10, 2021: BeyondSpring Pharmaceuticals announces analysis of new data on the plinabulin/pegfilgrastim combination in breast cancer at the 2021 San Antonio Breast Cancer Symposium

Dec 01, 2021: BeyondSpring Pharmaceuticals receives complete response letter from the FDA for plinabulin new drug application for prevention of chemotherapy-induced neutropenia (CIN)

Sep 16, 2021: BeyondSpring Pharmaceuticals announces new positive data on plinabulin from its chemotherapy-induced neutropenia prevention program at the European Society for Medical Oncology 2021 Congress

Sep 09, 2021: BeyondSpring announces three poster presentations about its chemotherapy-induced neutropenia prevention program at the European Society for Medical Oncology 2021 Congress

Jun 17, 2021: BeyondSpring to host R&D day to discuss novel immune agent Plinabulin’s development program in anti-cancer indications

Jun 10, 2021: BeyondSpring announces final positive data from the PROTECTIVE-1 phase 3 CIN program of plinabulin as a single agent compared to pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 08, 2021: BeyondSpring announces a late-breaking poster presentation of PROTECTIVE-2 phase 3 data showing plinabulin, in combination with pegfilgrastim, reverses the immune-suppressive effects of pegfilgrastim and offers superior prevention of chemotherapy-induced neutropenia (CIN) at the FOCIS Annual Meeting

Jun 07, 2021: BeyondSpring announces three presentations highlighting positive clinical outcome data from the phase 3 program of plinabulin in combination with pegfilgrastim for the prevention of Chemotherapy-induced neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 02, 2021: Lupin announces U.S. FDA acceptance for Pegfilgrastim biosimilar application

Jun 01, 2021: BeyondSpring announces U.S. FDA acceptance and priority review of new drug application for plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN)

Apr 28, 2021: BeyondSpring announces five presentations at the American Society of Clinical Oncology (ASCO) annual meeting

Mar 31, 2021: Evive Biotech submits biologics license application to US FDA for Ryzneuta

Mar 31, 2021: BeyondSpring announces submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Chemotherapy Induced Neutropenia – Pipeline by Apotex Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by BeyondSpring Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by Biocon Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Biosimilar Solutions LLC, 2022

Chemotherapy Induced Neutropenia – Pipeline by Bolder Biotechnology Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by Cellerant Therapeutics Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by CSPC Pharmaceutical Group Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Curateq Biologics Pvt Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Dr. Reddy’s Laboratories Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Enzychem Lifesciences Corp, 2022

Chemotherapy Induced Neutropenia – Pipeline by Evive Biotech, 2022

Chemotherapy Induced Neutropenia – Pipeline by FortuneRock (China) Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by General Regeneratives Shanghai Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by GlycoMimetics Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by Hangzhou Jiuyuan Gene Engineering Co Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Ilkogen Ilac San Ve Tic AS, 2022

Chemotherapy Induced Neutropenia – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Jiangsu T-mab BioPharma Co Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Karyo Biologics LLC, 2022

Chemotherapy Induced Neutropenia – Pipeline by Kidswell Bio Corp, 2022

Chemotherapy Induced Neutropenia – Pipeline by Ligand Pharmaceuticals Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by Lupin Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Mycenax Biotech Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by Pangen Biotech Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by Profarma, 2022

Chemotherapy Induced Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, 2022

Chemotherapy Induced Neutropenia – Pipeline by Richter Gedeon Nyrt, 2022

Chemotherapy Induced Neutropenia – Pipeline by Siam Bioscience Co Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Tanvex BioPharma Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by UBI Pharma Inc, 2022

Chemotherapy Induced Neutropenia – Pipeline by USV Pvt Ltd, 2022

Chemotherapy Induced Neutropenia – Pipeline by Valenta Pharm, 2022

Chemotherapy Induced Neutropenia – Pipeline by Xiamen Amoytop Biotech Co Ltd, 2022

Chemotherapy Induced Neutropenia – Dormant Projects, 2022

Chemotherapy Induced Neutropenia – Dormant Projects, 2022 (Contd..1)

Chemotherapy Induced Neutropenia – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

The key targets in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor, Caspase 3, Caspase 8, Caspase 9, Rho Guanine Nucleotide Exchange Factor 2, E Selectin, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha, Interleukin 1 Receptor, Signal Transducer And Activator Of Transcription, Signal Transducer and Activator Of Transcription 5.

The key MoA in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor Agonist, Caspase 3 Activator, Caspase 8 Activator, Caspase 9 Activator, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha Agonist, and Rho Guanine Nucleotide Exchange Factor 2 Activator.

The key RoA in the chemotherapy induced neutropenia pipeline market are subcutaneous, intravenous, oral, and intramuscular.

The key molecule type in the chemotherapy induced neutropenia pipeline market are recombinant protein, fusion protein, small molecule, and cell therapy.

The key companies in the chemotherapy induced neutropenia pipeline market are Curateq Biologics Pvt Ltd, Hanmi Pharmaceuticals Co Ltd, USV Pvt Ltd, BeyondSpring Inc, Biocon Ltd 1, Bolder Biotechnology Inc, Evive Biotech, and Lupin Ltd.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.